$1.15 EPS Expected for Medifast, Inc. (MED)

October 13, 2018 - By Hazel Jackson

Medifast, Inc. (NYSE:MED) LogoInvestors sentiment increased to 1.48 in Q2 2018. Its up 0.20, from 1.28 in 2018Q1. It is positive, as 18 investors sold Medifast, Inc. shares while 66 reduced holdings. 52 funds opened positions while 72 raised stakes. 10.04 million shares or 0.04% more from 10.03 million shares in 2018Q1 were reported.
Manufacturers Life Ins The owns 8,565 shares. 11,245 were reported by Comerica Bank. State Common Retirement Fund, New York-based fund reported 17,800 shares. 20,273 are held by Lazard Asset Mngmt Limited Liability Corporation. Mason Street Advsr Limited Liability Company invested 0.01% in Medifast, Inc. (NYSE:MED). North Star Corp holds 800 shares or 0.01% of its portfolio. Ny State Teachers Retirement System owns 11,811 shares for 0% of their portfolio. Tci Wealth Advsrs stated it has 5 shares or 0% of all its holdings. Credit Suisse Ag reported 0% in Medifast, Inc. (NYSE:MED). D E Shaw And reported 13,554 shares. 6,917 were accumulated by Sector Pension Board. Piedmont Invest Advisors Ltd Liability Corp accumulated 2,492 shares or 0.02% of the stock. Global X Mgmt Ltd Liability reported 190 shares. Bogle Invest Limited Partnership De, Massachusetts-based fund reported 79,954 shares. Louisiana State Employees Retirement Systems reported 4,800 shares stake.

Analysts expect Medifast, Inc. (NYSE:MED) to report $1.15 EPS on November, 6.They anticipate $0.60 EPS change or 109.09 % from last quarter’s $0.55 EPS. MED’s profit would be $13.74 million giving it 45.85 P/E if the $1.15 EPS is correct. After having $1.16 EPS previously, Medifast, Inc.’s analysts see -0.86 % EPS growth. The stock increased 4.28% or $8.65 during the last trading session, reaching $210.89. About 250,161 shares traded. Medifast, Inc. (NYSE:MED) has risen 363.41% since October 14, 2017 and is uptrending. It has outperformed by 347.79% the S&P500.

Medifast, Inc. (NYSE:MED) Ratings Coverage

Among 2 analysts covering Medifast (NYSE:MED), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Medifast had 2 analyst reports since April 19, 2018 according to SRatingsIntel. The company was downgraded on Thursday, April 19 by Sidoti. The rating was maintained by DA Davidson with “Buy” on Thursday, May 24.

Medifast, Inc., through its subsidiaries, produces, distributes, and sells weight loss, weight management, healthy living products, and other consumable health and diet products. The company has market cap of $2.52 billion. The firm offers bars, bites, pretzels, puffs, oatmeal and cereal crunch products, drinks, eggs, hearty choices, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, and soups under the Medifast, OPTAVIA, Thrive by Medifast, Optimal Health by Take Shape For Life, Flavors of Home, and Essential 1 brands, as well as Dual Fuel, a sports nutrition pilot program. It has a 63.52 P/E ratio. It also provides meal replacements comprising vitamins and minerals; and hydration products, as well as other nutrients for health purposes.

Another recent and important Medifast, Inc. (NYSE:MED) news was published by Investorplace.com which published an article titled: “Buy Medifast Stock as It Continues to Soar” on September 18, 2018.

Medifast, Inc. (NYSE:MED) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.